How ‘diabesity drugs’ could change the investment landscape

Trial results from Eli Lilly add to a growing body of evidence that suggests GLP-1 drugs, which include treatments like Lilly’s Mounjaro and Novo Nordisk’s Wegovy have medical benefits beyond diabetes and weight loss. Tematica CIO Chris Versace explains how these so-called ‘diabesity drugs‘ could affect healthcare and why their impact, positive and negative, could not be known for some time. He also discusses the impact of oil prices on monetary policy and Netflix.

Any opinion, news, research, analysis, or other information does not constitute investment or trading advice. 

Follow us on Twitter, Instagram, and YouTube 

*Your capital is at risk. 71% of retail CFD accounts lose money*